Prevalence of Au-Ag and Au-Ab in transfused children with thalassaemia in Greece

CHRISTOS KATTAMIS, VASILIKI SYRIOPOULOU, YIOULI DAVRI-KARAMOUZI, DEMETRIOS DEMETRIOU, and NICHOLAS MATSANIOTIS

From the Department of Paediatrics, 'St. Sophie's' Children's Hospital, Athens University, Greece

Epidemiological, clinical, biochemical, and histological studies have shown that the presence of Australia antigen (Au-Ag) is associated with infection with the virus of serum or type B hepatitis (Krugman, Giles, and Hammond, 1967, Blumberg et al., 1967). Though type B hepatitis can be transmitted by the oral route (Krugman and Giles, 1970), the most common route of infection is parenteral, mainly by transfusion of infected blood.

Au-Ag is detected during the incubation period and before the appearance of clinical or biochemical findings of hepatitis, and disappears usually within a few days or weeks. Some individuals carry Au-Ag for a long time; these long-term carriers are, as a rule, healthy; they have no clinical or biochemical evidence of hepatitis and may spread the virus to susceptible individuals. In some populations (mostly tropical) up to 20% of normal adults have been found to carry Au-Ag in their blood (Blumberg, Sutnick, and London, 1970).

The factors which lead to an individual becoming a long-term healthy Au-Ag carrier are unknown; it has been postulated that these factors are genetically determined by an autosomal recessive gene (Vierucci et al., 1972).

The factors regulating the synthesis of Au-Ab are also unclear. Very few patients with Au-Ag associated hepatitis synthesize Au-Ab, and this antibody is rarely detected in healthy individuals. It has been frequently detected, however, in hypertransfused patients with haemophilia, aplastic anaemia, or thalassaemia.

So far a limited number of studies on the incidence of Au-Ag and Au-Ab in thalassaemia have been reported and their results have been equivocal (Economidou et al., 1970, Vierucci et al., 1972).

This paper presents our findings on the prevalence of Au-Ag and Au-Ab in 196 transfused children with thalassaemia in Greece. The study was made in an attempt to define (a) the rate of infection with type B viral hepatitis by transfusion of patients with thalassaemia, (b) the duration of Au-Ag antigenaemia, and (c) the factors enhancing the synthesis of Au-Ab and the persistence of Au-Ab in thalassaemic patients.

Received 14 November 1973.
Prevalence of Au-Ag and Au-Ab in transfused children with thalassaemia in Greece

Material and methods

196 patients (94 males and 102 females) with homozygous β-thalassaemia, aged 10 months to 14 years, attending the Haemolytic Anaemia Unit of the Paediatric Department of Athens University, were studied. They were on different transfusion regimens in regard to pretransfusion Hb levels. However, most were on a frequent transfusion regimen, i.e. they were transfused when the Hb level fell to 8 g/100 ml.

More than 600 serum samples collected from these patients before transfusion on several occasions were tested for Au-Ag and Au-Ab by immunoelectro-osmophoresis, using 1% agarose in barbitone buffer, pH 8.2, and ionic strength 0.05 M. The antibody used was obtained from pooled sera from patients with homozygous β-thalassaemia who were frequently transfused.

Results

Prevalence of Au-Ag and Au-Ab. The results on the prevalence Au-Ag and Au-Ab among 196 children studied are summarized in Table I.

Au-Ag was detected in 14 (7%) and Au-Ab in 63 (32%) children. No difference in the prevalence of either Au-Ag or Au-Ab was found between boys and girls. None of these patients carried both Au-Ag and Au-Ab.

The persistence of Au-Ag in the 14 patients is illustrated in the Fig. Only 2 of these patients (Cases 1 and 14) had clinical and biochemical evidence of hepatitis and in both Au-Ag disappeared within about 1 month. In Case 1 antibody was detected after 2 months.

The remaining 12 patients had no clinical or biochemical evidence of hepatitis but Au-Ag persisted throughout the observation period, which varied from 5 to 18 months.

Relation of prevalence of Au-Ag and Au-Ab to age and number of transfused blood units. This is shown in Table II. It is evident that the

TABLE I

Prevalence of Au-Ag and Au-Ab in 196 children with β-thalassaemia

<table>
<thead>
<tr>
<th>Patients</th>
<th>No. of cases</th>
<th>Detection of Au-Ag</th>
<th>Detection of Au-Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>No. of cases</td>
<td>%</td>
</tr>
<tr>
<td>Males</td>
<td>94</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Females</td>
<td>102</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>196</td>
<td>14</td>
<td>7</td>
</tr>
</tbody>
</table>

Fig.—Persistence of Au-antigenaemia in 14 patients with thalassaemia.

TABLE II

Relation of prevalence of Au-Ag and Au-Ab to age and number of transfused blood units

<table>
<thead>
<tr>
<th>Groups</th>
<th>Total no. of cases</th>
<th>Detection of Au-Ag</th>
<th>Statistical analysis by $x^2$</th>
<th>Detection of Au-Ab</th>
<th>Statistical analysis by $x^2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td></td>
<td>No. of cases</td>
<td>%</td>
<td>Groups</td>
<td>P</td>
</tr>
<tr>
<td>I 1-4</td>
<td>58</td>
<td>6</td>
<td>10</td>
<td>I:II</td>
<td>&lt;0.03</td>
</tr>
<tr>
<td>II 5-8</td>
<td>98</td>
<td>7</td>
<td>7</td>
<td>II:III</td>
<td>&lt;0.03</td>
</tr>
<tr>
<td>III 9-14</td>
<td>40</td>
<td>1</td>
<td>2</td>
<td>I:III</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Transfu</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A 0-20</td>
<td>53</td>
<td>7</td>
<td>13</td>
<td>A:B</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>B 21-40</td>
<td>80</td>
<td>6</td>
<td>7</td>
<td>B:C</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>C 41-60</td>
<td>22</td>
<td>1</td>
<td>4</td>
<td>C:D</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>D &gt;60</td>
<td>41</td>
<td>0</td>
<td>0</td>
<td>A:D</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
incidence of Au-Ag decreases, whereas that of Au-Ab increases with increasing age.

The increase in the incidence of Au-Ab was more impressive in the older group (9–14 years) of patients with thalassaemia; in this group the incidence of Au-Ab was much higher (55%) than in the younger age group (14%).

The incidence of Au-Ab was proportional to the amount of blood transfused, whereas the incidence of Au-Ag appeared to be inversely proportional. Thus, the incidence of Au-Ag was considerably higher in those patients who had received less than 20 units of blood, than in those who had received 41 to 60 or > 60 blood units (Table II). In fact, the incidence of Au-Ag dropped to zero in the last group (P < 0.02).

On the contrary, the incidence of Au-Ab was considerably higher in the patients who had received more than 60 blood units. In this group the prevalence of Au-Ab was 61%, it was 11% in patients who had received 0 to 20 blood units, 29% in those who had received 21 to 40 units, and 41% in those who had received 41 to 60 units (Table II). In all patients the antibody, once detected, persisted throughout the observation period.

Discussion

Transfused patients with thalassaemia are in serious danger of infection with type B viral hepatitis, especially in countries where the incidence of healthy carriers of type B virus as determined by the detection of Au-Ag is high; in Greece the incidence of Au-Ag in healthy blood donors has been estimated to be 3% (Hadziyannis et al., 1970). However, we were impressed by the fact that transfused children with thalassaemia, closely followed-up at our unit, rarely showed clinical signs of viral hepatitis, and when they did the course of hepatitis was mild without serious complications, at least during the acute phase.

As indicated by the results of this study, the rate of infection with type B viral hepatitis, as determined by both the incidence of Au-Ag and Au-Ab, is extremely high. Nearly 40% of our patients had clear evidence of infection. A similar rate of infection was found in another series of Greek patients with thalassaemia, but a lower prevalence of Au-Ag (2%) and a higher prevalence of Au-Ab (40%) was reported (Economidou et al., 1970). In Italy the rate of infection with viral hepatitis in thalassaemic patients, though generally high, is lower than it is in Greece (Vierucci et al., 1972).

Epidemiological and clinical studies have shown an enormous variation in host response to infection with type B viral hepatitis, from acute hepatitis to the chronic carrier state of Au-Ag without evidence of hepatitis (Blumberg et al., 1970). It has also been shown in experiments using volunteers that 0.01 ml of icterogenic serum is as effective in causing infection as 200 times this amount (Cossart, 1972). Hence, it may be assumed that in practically any unit of blood with Au-Ag the effective amount of antigen is considerable. If this be true, the effect of transfusion of infected blood in patients with thalassaemia is determined mainly by host factors. In this respect, transfused patients with thalassaemia may be considered as an experimental model for the study of some of the unknown factors which determine the variable clinical response to type B viral infection.

One point which may lead to speculation is the prevalence and persistence of Au-Ag in our patients. In only 2 cases was Au-Ag associated with clinical symptoms and laboratory findings of liver involvement. In both these patients Au-Ag disappeared rapidly and in 1 of them it was followed by the production of Au-Ab. In the remaining 12 patients Au-Ag was not associated with either apparent clinical signs or biochemical evidence of liver impairment, and it persisted for the whole period of observation which varied between 5 and 18 months.

The persistence of Au-Ag in these patients is in contrast with the situation in acute viral hepatitis in which the presence of Au-Ag is transient and is detectable only for days or weeks (London, Sutnick, and Blumberg, 1969). On the other hand, the absence of clinical and biochemical evidence of hepatitis is similar to the situation in healthy carriers of Au-Ag. In our opinion, the persistence of Au-Ag in these patients can be explained only by assuming that such patients belong to a population which is susceptible to developing the state of long-term healthy carrier.

Blumberg et al. (1967) advanced the hypothesis that the persistence of the antigenaemia in some patients (i.e. with Down's syndrome, leukaemia) results from impairment of the immune system, probably impairment of cellular immunity. However, for the time being it is not clear whether the persistence of antigenaemia in patients with thalassaemia is due to recurrent infection transmitted by transfusion of infected blood, to the persistence of a single infection, or both. The answer may be found by long-term follow-up of Au-Ag positive thalassaemic patients, who upon detection of Au-Ag would be transfused with noninfected blood selected carefully by the most sensitive screening procedures in order to reduce the possibility of reinfection.

Another point which is difficult to explain is the
absence of clinical signs in most patients of this series infected by type B hepatitis virus. Undoubtedly, the young age of the patients was an important factor, since it is well known that hepatitis runs a very mild course and frequently is anicteric in children. Furthermore, in our experience there is no demonstrable difference in the clinical course and prognosis of hepatitis associated with Au-Ag and that not associated with Au-Ag. Another factor which could modify the clinical course of hepatitis in our patients is the fact that they were transfused with whole blood. Though the evidence on the preventive value of γ-globulin in type B hepatitis is still conflicting, the possibility of a favourable effect of regular transfusion of considerable amounts of plasma cannot be excluded in our patients.

The long-term prognosis of these patients, in whom the type B hepatitis apparently ran a mild clinical course with no serious complications during the acute phase, cannot be predicted with certainty. Vierucci et al. (1972) postulated that the persistence of Au-Ag in thalassaemic children contributes to early mortality. We were not able to confirm this assumption for we had no deaths during the observation period in our series, which consisted mainly of children below 12 years of age; it is our impression that some older patients developed clinical and biochemical signs of cirrhosis earlier than would have been expected from the number of transfusions and the degree of haemosiderosis, and that cirrhosis was associated with previous infection with type B viral hepatitis, since most of these patients had Au-Ab in their serum.

We were unable to confirm either the higher incidence of Au-Ag in males or the higher frequency of Au-Ab in females in published reports. In our series there were no sex differences in the incidence of Au-Ag and Au-Ab.

The last point to discuss is the factors enhancing Au-Ab synthesis. Au-Ab is detected in healthy individuals rarely and only exceptionally in patients with type B hepatitis. Undoubtedly the regulation of antibody synthesis is multifactorial, but the function of immune mechanism of the host and the way by which it is stimulated by the infectious agent are of primary importance. Clinical and experimental studies have shown that Au-Ab is usually produced after repeated infection with type B hepatitis. This explains the high incidence (61%) of Au-Ab in our patients who had received more than 60 blood units and its very low incidence (13%) in those who had received less than 20 blood units. In view of the high incidence of Au-Ab among blood donors in Greece, it may be assumed that hyper-transfused patients with thalassaemia have repeatedly received infected blood. We are led to conclude that repeated stimulation of the host's immune system by Au-Ab appears to be one of the factors regulating the production of Au-antibody.

We are grateful to the medical and nursing staffs of the Department of Paediatrics for help in the treatment of thalassaemic patients, and to Dr. Cleopatra Oconomou-Mavrou for editorial work.

REFERENCES


Correspondence to Dr. C. Kattamis, Athens University Department of Paediatrics, 'St. Sophie's' Children's Hospital, Athens 608, Greece.